NasdaqGS:DVAXBiotechs
Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders
Sanofi agreed to acquire Dynavax Technologies (NasdaqGS:DVAX) in a multi billion dollar deal.
The transaction focuses on adding Dynavax's approved hepatitis B vaccine and its experimental shingles vaccine to Sanofi's adult vaccines portfolio.
The deal is framed as an expansion of Sanofi's presence in adult immunizations.
Dynavax Technologies, known for its vaccine work including its hepatitis B product, sits at the intersection of adult immunization and broader infectious disease...